Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

News

Sygnature takes immense pride in its numerous accomplishments, fruitful research partnerships, and well-deserved awards. It is with great pleasure that we share these remarkable achievements at every available opportunity. Contained herein, you will have the opportunity to explore and be informed about the latest and most thrilling advancements taking place within our organization.

Filter by:

News Targeted Protein Degradation

Sygnature Discovery and UBE Corporation successfully identify potent SHP2 degrader compounds

READ ARTICLE

News

Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment

READ ARTICLE

News

Sygnature Discovery accelerates global growth with major North American acquisition

READ ARTICLE

News

Sygnature Discovery launches its in vivo LPS model to ​p​​rofile early-stage anti-inflammatory drugs​

READ ARTICLE

News

Sygnature Discovery and Daewoong Pharma announce research collaboration

READ ARTICLE

News

New platform set to accelerate early-stage targeted protein degradation

READ ARTICLE

News

Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

READ ARTICLE

News

Sygnature Discovery partners the Oncology Development Programme (ODP2) to find UK-based breakthroughs in Oncology

READ ARTICLE

News

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

READ ARTICLE

News

Sygnature Discovery acquires Peak Proteins

READ ARTICLE

News

500 – and counting!

READ ARTICLE

News

Taking a 3D view of heart failure with River BioMedics

READ ARTICLE
MORE...